Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...
The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of ...
Designing drugs is a bit like playing with Polly Pocket. The vintage toy is a plastic clam shell that contains a multi-bedroom house, a skating rink, a disco dance floor, and other fun scenarios. Kids ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine New antiviral drugs in development could offer the ...
Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...
Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...
Scientists led by a team at the Medical Research Council (MRC) Mitochondrial Biology Unit, University of Cambridge, have worked out how a molecular machine found in mitochondria—the “powerhouses” of ...
A version of this story appeared in Volume 103, Issue 11 Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising ...
Researchers discover new insights into how dual-target drug may supercharge cancer-fighting immune cells. Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback